Labor L+S AG and SYMBIOSIS Form Exclusive Business Alliance
News Apr 17, 2012
Labor L+S AG and SYMBIOSIS have announced that they have entered into an exclusive business alliance.
As of May 1st, 2012 Labor L+S AG will be able to offer to its customers comprehensive services and solutions in analytical testing of biopharmaceuticals and classical pharmaceuticals exclusively performed by SYMBIOSIS.
The business alliance with SYMBIOSIS expands the portfolio of Labor L+S AG and will enable clients of Labor L+S AG to order additional analytical services through a single point of contact, supporting all stages of the drug development life cycle and ensuring highest quality and improved cost and time efficiency for the benefit of its customers.
“Our goal at Labor L+S AG is to continuously extend the range of required services that meet the regulatory and scientific needs of our clients in the pharmaceutical and biotech industry. This business alliance with SYMBIOSIS enhances our ability to exceed client expectations by offering cost effective, innovative analytical services that accelerate the development, production and safety assessment of their pharmaceutical or biopharmaceutical product”, explains Dr. Lothar Bomblies, Member of the Management Board of Labor L+S AG.
Dr. Florian Wagner, CEO of Biopharm GmbH, comments: “We are proud to work together with the market leader in pharmaceutical microbiology in Germany. The continuously changing market demands of the life science industry require an expert partner with a broad range of services. This alliance brings together two well-established players in the German market, forming a powerful and innovative one-stop-shop service provider”.
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE
Chemists Design 'Mini-ecosystems' to Test Drug FunctionNews
Scripps Research scientists have solved a major problem in chemistry and drug development by using droplet-sized 'miniecosystems' to quickly see if a molecule can function as a potential therapeutic.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018